id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276197-gmx1p71j	Shen, Gwan-Han	Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions	2012-03-31		.txt	text/plain	3834	191	48	Abstract The role of fluoroquinolones (FQs) as empirical therapy for community-acquired pneumonia (CAP) remains controversial in countries with high tuberculosis (TB) endemicity owing to the possibility of delayed TB diagnosis and treatment and the emergence of FQ resistance in Mycobacterium tuberculosis. The role of fluoroquinolones (FQs) as empirical therapy for community-acquired pneumonia (CAP) remains controversial in countries with high tuberculosis (TB) endemicity owing to the possibility of delayed TB diagnosis and treatment and the emergence of FQ resistance in Mycobacterium tuberculosis. RFQs have been shown to have excellent activity against key causative pathogens of CAP as well as atypical pathogens; however, use of RFQs for empirical treatment of CAP might mask the diagnosis of tuberculosis (TB), leading to delayed treatment and FQ resistance amongst subsequently isolated Mycobacterium tuberculosis strains. In addition, we review the controversies surrounding the empirical use of FQs to treat patients with CAP, treatment options for patients with a delayed TB diagnosis, and the emergence of FQ resistance amongst M.	./cache/cord-276197-gmx1p71j.txt	./txt/cord-276197-gmx1p71j.txt